NeuWire Medical Announces FDA IDE Approval for STROKE-REWIRE Pivotal Study in Chronic Ischemic StrokeNeuWire Medical today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for STROKE-REWIRE, a pivotal study evaluating the ReWire Vagus Nerve Stimulation System in patients with chronic ischemic stroke and upper-limb dysfunction. The prospective, multicenter, randomized, sham-controlled study will enroll up to 135 participants across up to 12 U.S. clinical sites. Study initiation is expected in the first half of 2027, subject to institutional review board approvals and site readiness.
NeuWire Medical Appoints Ramin Mousavi as Executive Chairman Following Stroke Journal Publication.
NeuWire Medical, a medical device company advancing the development of a targeted plasticity therapy platform for individuals living with chronic ischemic stroke, today announced the appointment of Ramin Mousavi as Executive Chairman of the Board. His arrival marks an important step in the company’s next phase of growth as NeuWire Medical prepares to advance its clinical, regulatory, and financing strategy.
